Astellas U.S. LLC and Medivation Inc. announced that the results of the STRIVE trial to compare enzalutamide and bicalutamide in men with castration-resistant prostate cancer (CRPC) showed a statistically significant increase in progression-free survival (PFS) for men on enzalutamide.
The results of the STRIVE trial have been published online in the Journal of Clinical Oncology in an article titled "Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE Trial," which will also appear in the journal’s print edition in the future.
According to Medivation and Astellas, which is the U.S. subsidiary of Tokyo’s Astellas Pharma Inc., the STRIVE trial showed that enzalutamide resulted in a median PFS of 19.4 months, while the bicalutamide group’s median PFS was 5.7 months. The treatments presented similar rates of reported adverse events, with enzalutamide resulting in 29.4 percent and bicalutamide 28.3 percent.
Enzalutamide-treated patients had a slightly higher rate of grade III or higher cardiac adverse events, at 5.1 percent compared to bicalutamide’s rate of four percent. The enzalutamide group had one reported seizure. The enzalutamide group also reported known side effects of the treatment, including fatigue, back pain, hot flush, hypertension, dizziness and decreased appetite.
